Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 1142: Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models

Yann Wallez, Theresa Proia, Elisabetta Leo, Laura Bradshaw, Zena Wilson, Joe’l Owusu, Azadeh Cheraghchi-Bashi-Astaneh, Anna Staniszewska, Mark O’Connor, Sabina Cosulich, Jerome Mettetal

Cancer Res (2022) 82 (12_Supplement): 1142.

https://doi.org/10.1158/1538-7445.AM2022-1142

Published: 15 June 2022

View articletitled, Abstract 1142: Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models

Journal Articles

Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models

Yann Wallez, Theresa Proia, Azadeh Cheraghchi-Bashi-Astaneh, Ankur Karmokar, Zena Wilson, Suzanne Randle, Mark Anderton, Stephen Durant, Elisabetta Leo, Alan Lau, Mark O'Connor, Jerome Mettetal

Cancer Res (2022) 82 (12_Supplement): 5298.

https://doi.org/10.1158/1538-7445.AM2022-5298

Published: 15 June 2022

View articletitled, Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models

Journal Articles

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W.G. Wijnhoven, Adina M. Hughes, Joe Gerrard, Gemma N. Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A. Young, Mark J. O'Connor, Alan Lau

Cancer Res (2022) 82 (6): 1140–1152.

https://doi.org/10.1158/0008-5472.CAN-21-2997

Published: 15 March 2022

View articletitled, ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

Includes: Supplementary data

Journal Articles

Abstract P2-13-18: Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models

Theresa Proia, Yann Wallez, Azadeh Cheraghchi Bashi, Zena Wilson, Suzanne Randle, Mark Anderton, Danielle Carroll, Zeshaan Rasheed, J. Elizabeth Pease, Elisabetta Leo, Jerome Mettetal

Cancer Res (2022) 82 (4_Supplement): P2-13-18.

https://doi.org/10.1158/1538-7445.SABCS21-P2-13-18

Published: 15 February 2022

View articletitled, Abstract P2-13-18: Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models

Journal Articles

Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

James William Thomas Yates, Zena Wilson, Gemma N. Jones, Kevin Harrington, Matthew Krebs, Magnus Dillon, Andrew J. Pierce, Emma Dean, Alan Lau

Cancer Res (2020) 80 (16_Supplement): LB-104.

https://doi.org/10.1158/1538-7445.AM2020-LB-104

Published: 15 August 2020

View articletitled, Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Journal Articles

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Anna Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Maneesh Singh, Maryann San Martin, Zena Wilson, Theresa Proia, Oona Delpuech, Mark O'Connor, Elisabetta Leo, Viia Valge-Archer

Cancer Res (2020) 80 (16_Supplement): 967.

https://doi.org/10.1158/1538-7445.AM2020-967

Published: 15 August 2020

View articletitled, Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Journal Articles

Abstract 626: Mechanistic differentiation of targeted DDR agent combinations

Josep V. Forment, Paul Wijnhoven, Antonio Ramos-Montoya, Jacqueline Fok, Valeria Follia, Mercedes Vazquez-Chantada, Rajesh Oderda, Zena Wilson, Alan Lau, Elisabetta Leo, Stephen Durant, Elaine Cadogan, Mark J. O'Connor

Cancer Res (2020) 80 (16_Supplement): 626.

https://doi.org/10.1158/1538-7445.AM2020-626

Published: 15 August 2020

View articletitled, Abstract 626: Mechanistic differentiation of targeted DDR agent combinations

Journal Articles

Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Lucy A. Young, Lenka Oplustil O'Connor, Christelle de Renty, Margaret H. Veldman-Jones, Thierry Dorval, Zena Wilson, David R. Jones, Deborah Lawson, Rajesh Odedra, Apolinar Maya-Mendoza, Corinne Reimer, Jiri Bartek, Alan Lau, Mark J. O'Connor

Cancer Res (2019) 79 (14): 3762–3775.

https://doi.org/10.1158/0008-5472.CAN-18-2480

Published: 15 July 2019

View articletitled, Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Includes: Supplementary data

Journal Articles

Abstract 2826: Differential activity of ATR and WEE1 inhibitors in DLBCL subtypes is linked to replication stress and differences in mode of action

Lucy A. Young, Lenka Oplustil O'Connor, Zena Wilson, Corinne Reimer, Alan Lau, Jiri Bartek, Mark J. O'Connor

Cancer Res (2018) 78 (13_Supplement): 2826.

https://doi.org/10.1158/1538-7445.AM2018-2826

Published: 01 July 2018

View articletitled, Abstract 2826: Differential activity of ATR and WEE1 inhibitors in DLBCL subtypes is linked to replication stress and differences in mode of action

Journal Articles

Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models

Lucy A. Young, Oona Delpuech, Brandon Willis, Alexandra Bussey, Zena Wilson, Michelle Dupont, Carlos Grajales, Andrew Bloecher, Todd Covey, Kate Wills, Alan Lau, Simon J. Hollingsworth

Cancer Res (2018) 78 (13_Supplement): LB-263.

https://doi.org/10.1158/1538-7445.AM2018-LB-263

Published: 01 July 2018

View articletitled, Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models

Journal Articles

Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling

Alan Y. Lau, James Yates, Zena Wilson, Lucy A. Young, Adina M. Hughes, Alienor Berges, Amy Cheung, Rajesh Odedra, Elaine Brown, Mark J. O'Connor, Simon Hollingsworth

Cancer Res (2017) 77 (13_Supplement): 2494.

https://doi.org/10.1158/1538-7445.AM2017-2494

Published: 01 July 2017

View articletitled, Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling

Journal Articles

Abstract 1828: Are callipers obsolute? A novel 3D scanning technology to measure subcutaneous tumor volume

Zena Wilson, Juan Delgado, Michael Davies, Rebecca Whiteley, Jennifer Hare, Amar Rahi, Stephen Marshall, Andrew Smith, Stephen Atkinson, Jarno Ralli, Adeala Zabair, Adeala Zabair, Jane Kendrew

Cancer Res (2017) 77 (13_Supplement): 1828.

https://doi.org/10.1158/1538-7445.AM2017-1828

Published: 01 July 2017

View articletitled, Abstract 1828: Are callipers obsolute? A novel 3D scanning technology to measure subcutaneous tumor volume

Journal Articles

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

Cancer Res (2016) 76 (11): 3307–3318.

https://doi.org/10.1158/0008-5472.CAN-15-2357

Published: 31 May 2016

View articletitled, AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

Includes: Supplementary data

Journal Articles

Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow, Richard A. Norman, David Buttar, Gordon S. Currie, Hazel Weir, Craig Donald, David Andrews, Phil MacFaul, Peter Ballard, Jon Curwen, Zena Wilson, Graham Richmond, Celina D'Cruz, Steve Powell, Graeme Walker, Michael Hulse, Michael Tonge

Cancer Res (2015) 75 (15_Supplement): 3650.

https://doi.org/10.1158/1538-7445.AM2015-3650

Published: 01 August 2015

View articletitled, Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Journal Articles

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

Cancer Res (2015) 75 (15_Supplement): DDT01-03.

https://doi.org/10.1158/1538-7445.AM2015-DDT01-03

Published: 01 August 2015

View articletitled, Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1142: Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models

Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

Abstract P2-13-18: Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models

Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Abstract 626: Mechanistic differentiation of targeted DDR agent combinations

Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Abstract 2826: Differential activity of ATR and WEE1 inhibitors in DLBCL subtypes is linked to replication stress and differences in mode of action

Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models

Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling

Abstract 1828: Are callipers obsolute? A novel 3D scanning technology to measure subcutaneous tumor volume

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only